May 05, 2022
First quarter 2022 total revenue of $114.0 million , up 37% from $83.3 million for Q1 2021 HEPLISAV-B ® vaccine net product revenue of $20.8 million , up 151% from $8.3 million for Q1 2021 CpG 1018® adjuvant net product revenue of $91.5 million , up 23% from $74.6 million for Q1 2021 Guidance